3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other hematologic neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Leukemia, Myeloid, Acute
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma
1
Recurrence
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Melanoma
1
Lung Neoplasms
1
Liver Neoplasms
1
Leukemia
1
Kidney Neoplasms
1
High-risk Leukemias
1
Head and Neck Neoplasms
1
Glioblastoma
1
Esophageal Neoplasms
1
Disease
1
Colorectal Neoplasms
1
Carcinoma, Bronchogenic
1
Breast Neoplasms
1
Interventions
Gemcitabine
87
Cisplatin
66
Cystectomy
38
pembrolizumab
34
Docetaxel
25
Nivolumab
24
durvalumab
21
Paclitaxel
19
Magnetic Resonance Spectroscopy
18
Radiotherapy
17
Mitomycin
17
Carboplatin
16
atezolizumab
15
Doxorubicin
14
Cystoscopy
14
BCG Vaccine
13
Surveys and Questionnaires
12
Standard of Care
12
avelumab
11
Sunitinib
10
tremelimumab
9
Transurethral Resection of Bladder
9
Ipilimumab
9
Filgrastim
9
Blood Specimen Collection
9
Specimen Handling
8
Neoadjuvant Therapy
8
Methotrexate
8
Methods
8
Early Intervention, Educational
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Urinary Bladder Neoplasms
×
Interleukin-15
×
Clear all
NCT07410676
2026-02-18
EBNK-ST-001
Essen Biotech
Phase 1/2
Recruiting
83 enrolled